Drug Trial Radar · NCT07915245
A Study of LY4247147 in Participants With Obesity or Overweight Who Are Otherwise Healthy
Last checked: Nov 20, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
108
Planned (sponsor's estimate)
Start
Nov 6, 2026
Primary completion
Oct 2028
Study completion Oct 2028
Sponsor
- Lead sponsor
- Eli Lilly and CompanyEli Lilly (LLY)
- Sponsor type
- Industry
- First posted
- Nov 4, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The main purpose of this study is to understand how safe and well-tolerated LY4247147 is in participants with obesity or overweight who are otherwise healthy. Blood tests will be performed to check how much LY4247147 gets into the bloodstream and how long it takes the body to eliminate it. The study will be conducted in 3 parts. For each participant in Parts A and C, the study will last about 30 weeks and will include a stay in the Clinical Research Unit (CRU) lasting about 8 nights. For each participant in Part B, the study will last about 39 weeks and will include up to 3 stays in the CRU lasting about 9 nights each.
Conditions
- Obesity
- Overweight
Interventions
LY4247147Drug
administered SC
LY4247147Drug
administered IV
PlaceboDrug
administered SC
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part A and C: Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug AdministrationTime frame: Baseline through End of the Follow-up (Estimated as Week 25)
- Part B: Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug AdministrationTime frame: Baseline through End of the Follow-up (Estimated as Week 33)
Locations
3 sites in 2 countries. Site status is shown where the registry gives one.
ICON Early Phase Services Lenexa Center
Lenexa, Kansas · Recruiting
ICON
Salt Lake City, Utah · Not yet recruiting
Lilly Centre for Clinical Pharmacology
Singapore, Singapore · Not yet recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.